WO2010132370A3 - Soluble tlt-1 for the treatment and diagnosis of sepsis - Google Patents
Soluble tlt-1 for the treatment and diagnosis of sepsis Download PDFInfo
- Publication number
- WO2010132370A3 WO2010132370A3 PCT/US2010/034263 US2010034263W WO2010132370A3 WO 2010132370 A3 WO2010132370 A3 WO 2010132370A3 US 2010034263 W US2010034263 W US 2010034263W WO 2010132370 A3 WO2010132370 A3 WO 2010132370A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sepsis
- diagnosis
- treatment
- tlt
- soluble
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Abstract
The invention provides compositions including sTLT-1 and sTREM-1 polypeptides, the use of such polypeptides in therapeutic methods, and kits including such peptides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17724209P | 2009-05-11 | 2009-05-11 | |
US61/177,242 | 2009-05-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010132370A2 WO2010132370A2 (en) | 2010-11-18 |
WO2010132370A8 WO2010132370A8 (en) | 2011-08-11 |
WO2010132370A3 true WO2010132370A3 (en) | 2011-09-29 |
Family
ID=42985622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/034263 WO2010132370A2 (en) | 2009-05-11 | 2010-05-10 | Soluble tlt-1 for the treatment and diagnosis of sepsis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010132370A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
NZ602845A (en) | 2010-04-08 | 2015-05-29 | Inst Nat Sante Rech Med | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
EP3196214B1 (en) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
SI2814842T1 (en) | 2012-02-15 | 2018-10-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
JP6738316B2 (en) | 2014-07-17 | 2020-08-12 | ノヴォ ノルディスク アクティーゼルスカブ | Site-directed mutagenesis of TREM-1 antibody to reduce viscosity |
JP7023853B2 (en) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | Anti-TREM1 antibody and its usage |
JOP20190248A1 (en) | 2017-04-21 | 2019-10-20 | Amgen Inc | Trem2 antigen binding proteins and uses thereof |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
MX2021012365A (en) | 2019-04-17 | 2021-11-17 | Novo Nordisk As | Bispecific antibodies. |
CN113755580B (en) * | 2021-09-13 | 2023-10-27 | 中国医学科学院阜外医院 | Pharmaceutical intervention target for treating and/or relieving lymphedema and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040180409A1 (en) * | 2003-03-16 | 2004-09-16 | Mcvicar Daniel | TLT-1, a novel platelet-associated receptor and uses therefor |
US20080131423A1 (en) * | 2006-12-04 | 2008-06-05 | Government Of The Us, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions |
WO2009141359A1 (en) * | 2008-05-23 | 2009-11-26 | Pronota N.V. | New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof |
-
2010
- 2010-05-10 WO PCT/US2010/034263 patent/WO2010132370A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040180409A1 (en) * | 2003-03-16 | 2004-09-16 | Mcvicar Daniel | TLT-1, a novel platelet-associated receptor and uses therefor |
US20080131423A1 (en) * | 2006-12-04 | 2008-06-05 | Government Of The Us, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions |
WO2009141359A1 (en) * | 2008-05-23 | 2009-11-26 | Pronota N.V. | New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof |
Non-Patent Citations (6)
Title |
---|
FORD J W ET AL: "TREM and TREM-like receptors in inflammation and disease", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 1, 1 February 2009 (2009-02-01), pages 38 - 46, XP026104157, ISSN: 0952-7915, [retrieved on 20090221], DOI: DOI:10.1016/J.COI.2009.01.009 * |
GATTIS JAMES L ET AL: "The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 281, no. 19, 27 February 2006 (2006-02-27), pages 13396 - 13403, XP002589901, ISSN: 0021-9258, [retrieved on 20060501], DOI: DOI:10.1074/JBC.M600489200 * |
LU YEN-TA ET AL: "Preparation and characterization of monoclonal antibody against protein TREM-like transcript-1 (TLT-1)", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 25, no. 1, 1 February 2006 (2006-02-01), pages 20 - 26, XP002539976, ISSN: 0272-457X, DOI: DOI:10.1089/HYB.2006.25.20 * |
MORALES JESSICA ET AL: "Soluble TLT-1 modulates platelet-endothelial cell interactions and actin polymerization", BLOOD COAGULATION & FIBRINOLYSIS, RAPID COMMUNICATIONS, OXFORD, OXFORD, GB, vol. 21, no. 3, 1 April 2010 (2010-04-01), pages 229 - 236, XP009135455, ISSN: 0957-5235 * |
WASHINGTON A VALANCE ET AL: "A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets", BLOOD, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1042 - 1047, XP002627253, ISSN: 0006-4971 * |
WASHINGTON A VALANCE ET AL: "TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 119, no. 6, 11 May 2009 (2009-05-11), pages 1489 - 1501, XP002589557, ISSN: 0021-9738, DOI: DOI:10.1172/JC136175 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010132370A8 (en) | 2011-08-11 |
WO2010132370A2 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010132370A3 (en) | Soluble tlt-1 for the treatment and diagnosis of sepsis | |
WO2008100805A3 (en) | Anti-robo4 antibodies and uses therefor | |
WO2010034032A3 (en) | Methods for preparing purified polypeptide compositions | |
WO2011047087A3 (en) | Protein detection via nanoreporters | |
WO2008121767A3 (en) | Stitched polypeptides | |
WO2010083347A3 (en) | Peptidomimetic macrocycles | |
WO2011143624A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
WO2012088290A3 (en) | Tri-variable domain binding proteins and uses thereof | |
WO2009126292A3 (en) | Biologically active peptidomimetic macrocycles | |
WO2010083385A3 (en) | Compounds for reducing drug resistance and uses thereof | |
WO2012058393A3 (en) | Dkk1 antibodies and methods of use | |
ZA200800144B (en) | Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions | |
WO2012054638A3 (en) | Nmr systems and methods for the detection of analytes | |
MX355543B (en) | Peptidomimetic macrocycles. | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
WO2012020006A3 (en) | Anti-fap antibodies and methods of use | |
WO2009108860A8 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
WO2008097561A8 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
WO2012177595A9 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
WO2011011797A3 (en) | Cytokine compositions and methods of use thereof | |
WO2012173846A3 (en) | Peptidomimetic macrocycles | |
WO2010096604A3 (en) | Uses of cancer-targeting peptides in cancer diagnosis | |
WO2009100255A3 (en) | Modified leptin polypeptides and their uses | |
WO2010115118A3 (en) | Methods for preparing and using multichaperone-antigen complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10720070 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10720070 Country of ref document: EP Kind code of ref document: A2 |